BHC Soars As Bausch Health Earnings Beat Triggers Repricing

Bausch Health Companies Inc. surged as stocks have been trading up by 13.62 percent on stronger-than-expected earnings momentum.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading BHC

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Market Insights For BHC Traders

Q2 non-GAAP EPS of $1.26 topped $1.01 consensus, with revenue at $2.85B vs. $2.66B and the 13th straight quarter of revenue and adjusted EBITDA growth excluding Bausch + Lomb.
Management stressed strong adjusted operating cash flow and notable net debt reduction, pointing to greater financial flexibility.
2026 guidance calls for $10.79B–$11.04B in revenue and $4.05B–$4.175B in adjusted EBITDA, modestly above Street expectations.
Shares ripped roughly 26%–27% after the beat and raised 2026 outlook, signaling a sharp sentiment reset in BHC.
RBC Capital kept a Sector Perform rating with a $9 target, flagging Xifaxan patent litigation, possible Bausch + Lomb monetization, and forex as key swing factors.

Weekly Update Jul 27 – Jul 31, 2026: On Saturday, August 01, 2026 Bausch Health Companies Inc. stock [NYSE: BHC] is trending up by 13.62%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – positive

Bausch Health sits in a challenged but improving position: high‑margin (71% gross, ~18–19% EBITDA) branded/pharma assets, but structurally weak profitability (LTM profit margin about –11%) and very levered balance sheet (net debt ~US$20B, interest coverage only 1.2x, negative equity and BVPS). Nonetheless, Q2 showed clear progress: US$2.85B revenue, US$1.046B EBITDA and US$670M operating cash flow, with US$593M free cash flow, all validating the low 0.22x P/S and 1.1x cash‑flow multiples as deeply distressed, not growth, valuations.

The stock has broken from a tight 4.5–4.9 consolidation into a sharp momentum leg, jumping from ~US$4.6 to an intraday high above US$7, resolving a multi‑week base on expanding volume. The dominant trend on the weekly tape is now decisively bullish, with strong closes near the highs and minimal upper wicks. For trading, US$5.90–6.00 is the critical actionable level: sustained closes above that zone justify long entries with a first resistance/near‑term target at US$7.00–7.20.

More Breaking News

Fundamentally, Bausch is outperforming healthcare and pharma benchmarks on revenue and EBITDA growth but lags badly on balance sheet quality and GAAP returns. The upside surprise, raised 2026 guidance (US$10.79–11.04B revenue, US$4.05–4.18B EBITDA), and visible debt reduction are powerful positive catalysts. Litigation (Xifaxan), FX, and potential Bausch + Lomb monetization remain key swing factors. Base‑case outlook is constructive: accumulate with a 6–12 month price target of US$9 and technical support at US$5.75; strong resistance sits near US$9–10.

Quick Financial Overview

Bausch Health Companies Inc. just delivered the kind of quarter that forces traders to re-mark their levels. Q2 revenue landed near $2.85B versus $2.66B expected, with non-GAAP EPS at $1.26 versus $1.01. That marks the 13th straight quarter of year-over-year revenue and adjusted EBITDA growth (excluding Bausch + Lomb), which shows consistent execution rather than a one-off spike.

Under the hood, BHC generated about $670M in operating cash flow and $593M in free cash flow for the quarter, while also cutting net debt. With trailing revenue around $10.27B and an enterprise value near $30.11B, the stock trades at roughly 0.22 times sales and about 1.1 times cash flow, signaling a low multiple market despite a solid 71% gross margin and 18.7% EBITDA margin. The flip side is clear: heavy leverage, negative book value, and interest coverage of roughly 1.2 keep financial risk front and center.

On the chart, the reaction has been explosive. BHC jumped from the low-$4s to close near $4.88 on 2026/07/29, then gapped above $6.00 on 2026/07/30 and pushed toward $5.92. By 2026/07/31, price extended to roughly $6.85, with intraday action swinging between about $5.98 and $6.92 before closing strong near $6.89. For short-term traders, that creates a new support zone around $5.80–$6.00 and resistance near $7.00.

Conclusion

BHC Trading Setup After The Earnings Shock

Bausch Health Companies Inc. has shifted from slow grind to momentum name after this Q2 print. The combination of a clean beat on EPS and revenue, a long streak of adjusted EBITDA growth, and 2026 guidance above consensus gave traders a concrete reason to chase. Add in strong operating cash flow and net debt reduction, and the tape is now telling a different story than the low valuation multiples might suggest.

For BHC, the near-term trade is about whether the post-earnings surge can hold above the $5.80–$6.00 breakout band and build a base under $7.00. The risk side is not trivial: leverage is high, interest coverage is tight, and RBC has reminded the market that Xifaxan patent litigation, Bausch + Lomb monetization decisions, and forex swings can still hit the narrative. Those factors can turn volatility against late entries if headlines shift. This is exactly where trading discipline matters most. As Tim Bohen, lead trainer with StocksToTrade says, “For me, trading is more about managing risk than finding the next big mover.” In the context of BHC, that means sizing correctly, honoring your stops, and not assuming every breakout will run in a straight line.

Traders should treat Bausch Health Companies Inc. as a momentum-plus-catalyst name for now: strong trend, but still a turnaround balance sheet. As I teach my students, “When a beaten-down stock rips on real numbers and guidance, you trade the levels, not the hype — respect the new trend, but always map where you are wrong.” This framework keeps the focus on risk control while you study how BHC behaves around its new price range.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!